Table 1.

Univariate Cox and logistic regression within tumor subtypes and multivariate Cox and logistic regression in patients with HR+/HER2− breast cancer for comparing tumors with high vs. low HLA class I immunohistochemistry

Univariate Cox regression—disease-free survival (GeparTrio)
Subtype	MHCI	HR	95% CI	P
HR+/HER2−	High vs. low	1.590	1.062–2.380	0.024
HR−/HER2−	High vs. low	0.649	0.315–1.336	0.241
HR+/HER2+	High vs. low	2.486	0.956–6.467	0.062
HR−/HER2+	High vs. low	1.015	0.304–3.384	0.981
Multivariate Cox regression—disease-free survival (GeparTrio; HR+/HER2−)
		HR	95% CI	P
Response	pCR vs. RD	0.457	0.225–0.925	0.029
cT stage	cT3–4 vs. cT1–2	2.270	1.522–3.385	< 0.001
cN stage	cN+ vs. cN−	2.026	1.335–3.075	0.001
Therapy	Resp. guided vs. standard	0.945	0.638–1.400	0.777
Grade	G3 vs. G1–2	1.733	1.024–2.932	0.041
Age	Age ≥ 50 vs. < 50	1.252	0.838–1.870	0.272
HLA class I HC	High vs. low	1.701	1.105–2.618	0.016
Univariate logistic regression—pCR (GeparTrio)
Subtype	MHCI	HR	95% CI	P
HR+/HER2−	High vs. low	2.226	1.154–4.585	0.022
HR−/HER2−	High vs. low	0.852	0.332–2.316	0.744
HR+/HER2+	High vs. low	2.022	0.728–6.590	0.202
HR−/HER2+	High vs. low	0.857	0.220–3.385	0.823
Multivariate logistic regression—pCR (GeparTrio; HR+/HER2−)
		HR	95% CI	P
cT stage	cT3–4 vs. cT1–2	0.946	0.447–1.903	0.880
cN stage	cN+ vs. cN-	1.107	0.579–2.135	0.760
Therapy	Resp. guided vs. standard	0.842	0.444–1.578	0.593
Grade	G3 vs. G1–2	2.804	1.348–5.644	0.005
Age	Age ≥ 50 vs. < 50	0.564	0.297–1.055	0.075
HLA class I HC	High vs. low	2.132	1.057–4.603	0.042